TY - JOUR T1 - What Surveillance Plan Should Be Advised for Patients in Remission After Completion of First-Line Therapy for Advanced Ovarian Cancer? JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - S27 LP - S28 DO - 10.1111/IGC.0b013e3181f63a28 VL - 20 IS - Suppl 2 AU - Gordon J. S. Rustin Y1 - 2010/09/01 UR - http://ijgc.bmj.com/content/20/Suppl_2/S27.abstract N2 - Based on the results of the Medical Research Council OVO5/European Organisation for Research and Treatment of Cancer 55955 trial, the follow-up plan I recommend for patients in remission after completion of first-line therapy for advanced ovarian cancer is appointments: every 3 months for 2 years, every 4 months on the third year, then every 6 months thereafter, and discharge if no relapse by 10 years. History and examination (not internal) should be performed at each appointment. CA-125 should only be measured if there is a suspicion of relapse or at patient's request. No scans should be performed unless clinical indication or rising CA-125. ER -